Is Blue Lotus (Nymphaea caerulea) Legal in Georgia? (2026)

Instrument

statute

Source

https://codes.findlaw.com/ga/title-16-crimes-and-offenses/ga-code-sect-16-13-25/

Retrieved

2026-06-19

Fingerprint

975ce376a9303cbe

**§ 16-13-25(3)** "Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers (whether optical, position, or geometrics), and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: … **(YYY) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET)** …"
— O.C.G.A. § 16-13-25(3)(YYY); text via FindLaw mirror (labeled), "Current as of March 28, 2024": https://codes.findlaw.com/ga/title-16-crimes-and-offenses/ga-code-sect-16-13-25/
Companion prodrug separately listed: "(PPP) 4-acetoxy-N-ethyl-N-methyltryptamine (4-AcO-MET)."
— same section/source

Instrument

O.C.G.A. 16-13-25 (Schedule I): 2025-2026 amending bills only

Source

https://www.legis.ga.gov/api/legislation/document/20252026/242800

Retrieved

2026-10-08

Fingerprint

9aca7ce7e83f4f83

LC 65 0071 House Bill 1329 By: Representatives Stephens of the 164th and Newton of the 127th A BILL TO BE ENTITLED AN ACT To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, so as to provide for certain provisions relating to Schedule I controlled substances; to provide for certain provisions relating to the definition of dangerous drugs; to provide for related matters; to provide for an effective date; to repeal conflicting laws; and for other purposes. BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA: SECTION 1. Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, is amended in Code Section 16-13-25, relating to Schedule I controlled substances, by revising subparagraph (E) of paragraph (16) as follows: "(E) By substitution at the 5-position or 6-position with a nitro, alkyl, halide, cyano, or acetyl group or primary amine;" SECTION 2. Said chapter is further amended in Code Section 16-13-71, relating to dangerous drug, by adding new paragraphs to subsection (b) to read as follows: H. B. 1329 -1- LC 65 0071 "(1.5) Aceclidine;" "(12.7) Acoltremon;" "(17.2) Aficamten;" "(68.45) Atrasentan;" "(69.21) Avutometinib;" "(91.71) Berahyaluronidase alfa-pmph;" "(106.4) Brensocatib;" "(196.3) Clesrovimab-cfor;" "(240.97) Datopotamab deruxtecan-dlnk;" "(243.4) Defactinib;" "(244.7) Delgocitinib;" "(248.5) Depemokimab-ulaa;" "(316.6) Donidalorsen;" "(317.15) Dordaviprone;" "(318.7) Doxecitine;" "(320.5) Doxribtimine;" "(331.0513) Elamipretide;" "(331.0555) Elinzanetant;" "(379.8) Etripamil;" "(386.95) Fitusiran;" "(411.9) Garadacimab-gxii;" "(414.4) Gepotidacin;" "(466.7) Imlunestrant;" "(513.75) Lerodalcibep-liga;" "(523.5) Linvoseltamab-gcpt;" "(619.15) Mirdametinib;" "(640.105) Nerandomilast;" H. B. 1329 -2- LC 65 0071 "(644.605) Nipocalimab-aahu;" "(663.65) Onasemnogene abeparvovec-brve;" "(681.65) Paltusotine;" "(698.5) Penpulimab-kcqx;" "(742.7) Plozasiran;" "(768.6) Prademagene zamikeracel;" "(832.975) Remibrutinib;" "(836.6) Revakinagene taroretcel-lwey;" "(842.3) Rilzabrutinib;" "(852.055) Sebetralstat;" "(855.1) Sepiapterin;" "(855.735) Sevabertinib;" "(855.83) Sibeprenlimab-szsi;" "(927.8) Sunvozertinib;" "(929.7) Suzetrigine;" "(930.978) Taletrectinib;" "(931.565) Telisotuzumab vedotin-tllv;" "(974.65) Treosulfan;" "(1030.9) Vimseltinib;" "(1042.2) Ziftomenib;" "(1042.85) Zoliflodacin;" "(1042.91) Zongertinib;" "(1042.93) Zopapogene imadenovec-drba;" SECTION 3. Said chapter is further amended in subsection (b) of said Code section by repealing and reserving paragraph (324) and by revising paragraphs (60.3), (160.5), and (217.2) as follows: H. B. 1329 -3- LC 65 0071 "(60.3) Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl;" "(160.5) Chikungunya vaccine, Live;" "(217.2) COVID-19 Vaccine, mRNA;" SECTION 4. Said chapter is further amended in subsection (c) of said Code section by revising paragraph (9.33) as follows: "(9.33) Epinephrine , : (A) When when used in a device that delivers a metered spray of 0.125 mg. of epinephrine or less to provide temporary relief for symptoms of mild, intermittent asthma and is a product in finished dosage formulation in its original container that has been approved by and labeled in compliance with the U.S. Food and Drug Administration (FDA); and (B) When distributed by a pharmacist as provided by the State Board of Pharmacy, in a device that delivers a spray of 2 mg. of epinephrine or less to provide emergency treatment of allergic reactions, including anaphylaxis, and is a product in finished dosage formulation in its original container that has been approved by and labeled in compliance with the U.S. Food and Drug Administration (FDA);" SECTION 5. This Act shall become effective upon its approval by the Governor or upon its becoming law without such approval. SECTION 6. All laws and parts of laws in conflict with this Act are repealed. H. B. 1329 -4-

Instrument

Schedule I -- Hallucinogens (Georgia Board of Pharmacy scheduling rule placing 5-MAPB under O.C.G.A. 16-13-25(3))

Source

https://rules.sos.ga.gov/gac/480-34-.07

Retrieved

2026-07-20

Fingerprint

536dedc5bafa1575

(1) This rule was adopted to protect the health, safety, and welfare of the public. This rule places additional newly identified compounds, including any material, compound, mixture, or preparation which contains any quantity of the following substances, their salts, isomers (whether optical, position, or geometrics), and salts of isomers under Schedule I of the Georgia Controlled Substances Act, Section 16-13-25(3) as follows: (BBBB) Methoxyphencyclidine (MeO-PCP); (CCCC) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-OH-MiPT); (DDDD) N,[ALPHA]-dimethyl-5-benzofuranethanamine (5-MAPB); (EEEE) 1-pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide (SDB-006); (FFFF) methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA). (2) This rule is based on the following findings of the Board: (a) that hallucinogens have an extremely high potential for abuse; (b) that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances; (c) that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation; (d) that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds; (e) that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act; and (f) that these compounds have no known precursor already scheduled under the Act.